NCT04696029 2026-03-02
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06465199 2026-03-02
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT04301843 2026-02-03
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02679144 2026-01-21
NMTT
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05717153 2025-11-04
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT06892678 2025-05-11
DFMO
Montefiore Medical Center
Phase 1/2 Recruiting